Anders Björklund Selected Research

eltoprazine

4/2015	Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
7/2013	Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anders Björklund Research Topics

Disease

71	Parkinson Disease (Parkinson's Disease) 10/2021 - 04/2002
29	Dyskinesias (Dyskinesia) 01/2020 - 07/2002
5	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020 - 07/2003
2	Nerve Degeneration 10/2018 - 07/2014
2	Synucleinopathies 01/2017 - 03/2003
2	Disease Progression 01/2017 - 05/2013
1	Wounds and Injuries (Trauma) 01/2020
1	Dizziness (Lightheadedness) 04/2015
1	Nausea 04/2015
1	Huntington Disease (Huntington's Disease) 04/2012
1	Hallucinations (Hallucination) 04/2012
1	Asthenopia (Eyestrain) 04/2012
1	Neoplasms (Cancer) 06/2010
1	Hyperkinesis 03/2006
1	Neuritis (Polyneuritis) 03/2003

Drug/Important Bio-Agent (IBA)

32	Dopamine (Intropin)FDA LinkGeneric 01/2021 - 07/2002
24	Levodopa (L Dopa)FDA LinkGeneric 01/2020 - 07/2002
13	Serotonin (5 Hydroxytryptamine)IBA 11/2017 - 07/2007
10	SynucleinsIBA 01/2021 - 01/2010
9	Oxidopamine (6 Hydroxydopamine)IBA 01/2021 - 07/2002
6	Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA 01/2021 - 02/2004
3	Amphetamine (Amfetamine)FDA LinkGeneric 01/2019 - 06/2012
3	Neurotransmitter Agents (Neurotransmitter)IBA 01/2017 - 01/2008
3	Proteins (Proteins, Gene)FDA Link 10/2015 - 07/2003
3	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 12/2013 - 12/2008
3	Therapeutic UsesIBA 07/2013 - 08/2011
3	alpha-SynucleinIBA 05/2008 - 04/2002
3	Pharmaceutical PreparationsIBA 01/2008 - 07/2002
2	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2020 - 11/2017
2	NeurotoxinsIBA 01/2019 - 08/2011
2	eltoprazineIBA 04/2015 - 07/2013
2	Dopamine Receptors (Dopamine Receptor)IBA 07/2013 - 01/2010
2	Transcription Factors (Transcription Factor)IBA 02/2013 - 12/2009
2	5-HT1B Serotonin ReceptorIBA 09/2009 - 12/2008
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020
1	Synapsins (Synapsin I)IBA 10/2018
1	Nerve Growth Factors (Neurotrophins)IBA 11/2017
1	BenserazideIBA 11/2017
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 12/2015
1	LigandsIBA 10/2015
1	Retinoid X Receptors (Retinoid X Receptor)IBA 10/2015
1	Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA 04/2015
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 07/2014
1	anpirtolineIBA 12/2013
1	TOR Serine-Threonine KinasesIBA 05/2013
1	temsirolimus FDA Link 01/2013
1	NeurturinIBA 12/2012
1	Neuroprotective AgentsIBA 08/2011
1	antineoplaston A10 (A 10)IBA 02/2010
1	5-HT1 Serotonin ReceptorsIBA 09/2009
1	Serotonin 5-HT1 Receptor AgonistsIBA 07/2007
1	salicylhydroxamic acid (SHAM)IBA 03/2006
1	Methamphetamine (Desoxyn)FDA LinkGeneric 12/2005
1	SuspensionsIBA 07/2005
1	EnzymesIBA 03/2005
1	GTP Cyclohydrolase (GTP Cyclohydrolase I)IBA 03/2005
1	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA 03/2005
1	Dihydroxyphenylalanine (Dopa)IBA 03/2005

Therapy/Procedure

20	Therapeutics 10/2021 - 01/2005
18	Transplantation 10/2021 - 07/2002
7	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2021 - 10/2004
5	Cell Transplantation 01/2016 - 02/2005
4	Injections 01/2019 - 07/2002
1	Deep Brain Stimulation 01/2021
1	Autologous Transplantation 01/2020
1	Denervation 07/2002